Features

Our editorial board comprises a specialist group of leading industry figures who, in conjunction with the World Pharmaceutical Frontiers editorial team, identify the main drivers of the industry helping to produce regular, thought-provoking opinion pieces on the latest issues, challenges and developments.

Latest World Pharmaceuticals Feature

A matter of time
25 May, 2021
Without lipid nanoparticles, there’s no mRNA vaccine, no 95% efficacy,...
> read more

Root and branch 25 May, 2021 Pharmaceutical companies were setting ambitious deadlines for improving supply chain sustainability prior to Covid-19. The pandemic has since laid bare their reliance on complex chains...

War and IPs 25 May, 2021 Like never before, the pharmaceutical supply chain is a geopolitical arena, but when every surge of the virus and variation in vaccine yield raises the stakes, familiar...

Pathway to excipients 25 May, 2021 Innovation in drug development has continued at an often dizzying pace during the pandemic, but in the area of excipients, it’s hampered by a burdensome regulatory process. Kim...

Track and trace 25 May, 2021 There’s nothing like a pandemic for demonstrating the necessity for serialisation, interoperability, and more advanced analytics and tracking. Tim Gunn asks Rob Handfield, the...

Close of play 25 May, 2021 Given the lack of standardisation on shape, size and material for closed-system transfer devices (CSTDs), many pharmaceutical companies are struggling to ensure their products work...

4.0 lights the way 25 May, 2021 It might sound like the latest software update for your iPhone, but Industry 4.0 is sending shockwaves through manufacturing industries. Mae Losasso speaks to Ian Cronin, project lead...

Life transport 12 April, 2021 Intricate supply chains have been a part of medical life for decades – but nowhere are they more complex than in the field of cell and gene therapy. Many treatments are...

Twisted system 12 April, 2021 If you wanted to devise a test for how well pharma has optimised its logistics, you couldn’t do much better than asking the industry to build the supply chains for Covid-19...

Travel risk 12 April, 2021 It’s not just shifting portfolios and expanding markets that supply chain strategies need to take into account. Our understanding of what constitutes an effective cold chain...

Vial bodies 12 April, 2021 The global Covax initiative aims to produce two billion doses of Covid-19 vaccines by 2021 – without building any new factories. That’s going to take a lot of flexible,...

Black swan theory 12 April, 2021 Covid-19 has ruthlessly exposed pharmaceutical supply chain issues, raising one huge question for companies and governments across Europe and North America: is it time to...

Development from home 12 April, 2021 There’s nothing like a global pandemic for driving interest in remote drug development – but can computer-aided biology change how drugs are designed in the long term, or is it just...

Natural reaction 12 April, 2021 There are 12 green chemistry principles. Using biocatalysis to synthesise pharmaceuticals fulfils the requirements of ten of them – with the other two not applicable. But...

Water solvable 12 April, 2021 Pharmaceutical development is a delicate balance of stability, manufacturability and bioavailability. For all the advantages that lipid-based excipients (LBEs) bring to the...

Make it warp 12 April, 2021 Given the rapid innovation in drug modalities and the jet engine that Covid-19 has strapped to concepts of patient-centred design and digital health, it looks increasingly unlikely...

A standardised approach 29 December, 2020 Douglas Fiebig, PhD, senior partner of Trilogy Writing & Consulting, Frankfurt, Germany, discusses the challenges encountered when responding to medical writing RFIs.

A trial run 29 December, 2020 What a difference a pandemic makes. Clinical trials that would previously have taken years to design and conduct have delivered results in under 12 months, and stages once...

Support systems 29 December, 2020 For years, the patient-centric promise of the decentralised trial was little more than a utopian dream. But, with a global pandemic keeping people in their homes, 2020 brought the...

Get the gears turning 29 December, 2020 The demand for comparator products in clinical trials is growing rapidly, but the sourcing models are uniquely susceptible to blockages in the supply chain. Jim Banks asks Steven...


View all features A-Z


Privacy Policy
We have updated our privacy policy. In the latest update it explains what cookies are and how we use them on our site. To learn more about cookies and their benefits, please view our privacy policy. Please be aware that parts of this site will not function correctly if you disable cookies. By continuing to use this site, you consent to our use of cookies in accordance with our privacy policy unless you have disabled them.